Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

Mediators of Inflammation

Volumn 2005, Issue 5, 2005, Pages 273-279

  Arican, Ozer ^a   Aral, Murat ^a   Sasmaz, Sezai ^a   Ciragil, Pinar ^a  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PARAMETER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKINS; MALE; MIDDLE AGED; PSORIASIS; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27644565806     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI.2005.273     Document Type: Article

References (43)

1. Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin. 2004;22(4):349-369.
2. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999;20(1):40-46.
3. Griffiths CEM. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2):1-5.
4. Chamian F, Krueger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol. 2004;16(4):331-337.
5. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004;135(1):1-8.
6. Fry L. Psoriasis. Br J Dermatol. 1988;119(4):445-461.
7. Lever WF, Schaumburg-Lever G. Histopathology of the Skin. Philadelphia, Pa: JB Lippincott; 1975:135-146.
8. McKenzie RC, Sauder DN. The role of keratinocyte cytokines in inflammation and immunity. J Invest Dermatol. 1990;95(suppl 6):105S-107S.
9. Thomson A. The Cytokine Handbook. 3rd ed. New York, NY: Academic Press; 1998.
10. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol. 1999;38(4):241-251.
11. Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991;138(1):129-140.
12. Prinz JC. Which T cells cause psoriasis? Clin Exp Dermatol. 1999;24(4):291-295.
13. Uyemura K, Yamamura M, Fivenson DF,Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101(5):701-705.
14. De Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatol Ther. 2004;17(5):341-349.
15. Jacob SE, Nassiri M, Kerdel FA, Vincek V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm. 2003;12(5):309-313.
16. El Barnawi NY, Giasuddin ASM, Ziu MM, Singh M. Serum cytokine levels in psoriasis vulgaris. Br J Biomed Sci. 2001;58(1):40-44.
17. Szegedi A, Aleksza M, Gonda A, et al. Elevated rate of T-helper1 (T(H)1) lymphocytes and serum IFN-γ levels in psoriatic patients. Immunol Lett. 2003;86(3):277-280.
18. Gomi T, Shiohara T, Munakata T, Imanishi K, Nagashima M. Interleukin 1α, tumor necrosis factor α, and interferon γ in psoriasis. Arch Dermatol. 1991;127(6):827-830.
19. Abanmi A, Al Harthi F, Al Agla R, Khan HA, Tariq M. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol. 2005;44(1):82-83.
20. Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11(3):115-118.
21. Chodorowska G. Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol. 1998;10(2):147-151.
22. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-α, IL-1β and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci. 1997;14(2):145-153.
23. Okubo Y, Koga M. Peripheral blood monocytes in psoriatic patients overproduce cytokines. J Dermatol Sci. 1998;17(3):223-232.
24. Szepietowski JC, Bielicka E, Nockowski P, Noworolska A, Wasik F. Increased interleukin-7 levels in the sera of psoriatic patients: lack of correlations with interleukin-6 levels and disease intensity. Clin Exp Dermatol. 2000;25(8):643-647.
25. Biasi D, Carletto A, Caramaschi P, et al. Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. Inflammation. 1998;22(5):533-543.
26. Pietrzak A, Koziol-Montewka M, Lecewicz-Torun B, Krasowska D. Is there any correlation between the total number of neutrophils in plasma and concentration of interleukin-8 in psoriatic patients? Med Sci Monit. 2000;6(5):867-870.
27. Gangemi S, Merendino RA, Guarneri F, et al. Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis: preliminary considerations. J Eur Acad Dermatol Venereol. 2003;17(1):42-46.
28. Sehgal PB. Interleukin-6: molecular pathophysiology. J Invest Dermatol. 1990;94(suppl 6):2S-6S.
29. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13(4-5):357-368.
30. Sticherling M, Sautier W, Schroder JM, Christophers E. Interleukin-8 plays its role at local level in psoriasis vulgaris. Acta Derm Venereol. 1999;79(1):4-8.
31. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111(6):1053-1057.
32. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123(6):1037-1044.
33. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111(suppl 2):S460-S475.
34. Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 upregulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol. 1998;161(7):3400-3407.
35. Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest. 1999;104(6):761-767.
36. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999;103(1 pt 1):11-24.
37. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004;61(5):567-579.
38. Teunissen MBM, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111(4):645-649.
39. Spriggs MK. Interleukin-17 and its receptor. J Clin Immunol. 1997;17(5):366-369.
40. Piskin G, Tursen U, Sylva-Steenland RMR, Bos JD, Teunissen MB. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-γ inducers - IL-12, IL-18 and IL-23. Exp Dermatol. 2004;13(12):764-772.
41. Asadullah K, Sterry W, Volk HD. Analysis of cytokine expression in dermatology. Arch Dermatol. 2002;138(9):1189-1196.
42. Williams JDL, Griffiths CEM. Cytokine blocking agents in dermatology. Clin Exp Dermatol. 2002;27(7):585-590.
43. Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4(1):19-34.